Safety and efficacy of denosumab in osteoporotic patients previously treated with other medications: a systematic review and meta-analysis

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Expert Opinion on Drug Safety

• Publication date

  2018-01-25

• Fields of study

  Medicine

• Identifiers
  DOI 10.1080/14740338.2018.1430764PMID 29350565
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Adjudication of osteonecrosis of the jaw in phase III randomized controlled trials of denosumab: a systematic review

  2017influential reference
• 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension.

  2017cited by this paper
• Natural history, reasons for, and impact of low/non-adherence to medications for osteoporosis in a cohort of community-dwelling older women already established on medication: a 2-year follow-up study

  2016cited by this paper
• Denosumab or Zoledronic Acid in Postmenopausal Women With Osteoporosis Previously Treated With Oral Bisphosphonates

  2016influential reference
• BEYOND DXA: ADVANCES IN CLINICAL APPLICATIONS OF NEW BONE IMAGING TECHNOLOGY.

  2016cited by this paper
• Effect of Denosumab on Bone Mineral Density and Markers of Bone Turnover among Postmenopausal Women with Osteoporosis

  2016influential reference
• Effects of denosumab on bone mineral density and renal function in postmenopausal women transitioning from raloxifene

  2015influential reference
• Denosumab versus zoledronic acid in patients previously treated with zoledronic acid

  2015influential reference
• Persistence, adherence, and medication-taking behavior in women with postmenopausal osteoporosis receiving denosumab in routine practice in Germany, Austria, Greece, and Belgium: 12-month results from a European non-interventional study

  2015cited by this paper
• Does salmon calcitonin cause cancer? A review and meta-analysis

  2015cited by this paper
• Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial.

  2015influential reference
• The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study

  2015cited by this paper
• Denosumab in treatment-naïve and pre-treated with zoledronic acid postmenopausal women with low bone mass: Effect on bone mineral density and bone turnover markers.

  2015cited by this paper
• Indirect comparison of teriparatide, denosumab, and oral bisphosphonates for the prevention of vertebral and nonvertebral fractures in postmenopausal women with osteoporosis

  2015cited by this paper
• The effects of switching daily teriparatide to oral bisphosphonates or denosumab in patients with primary osteoporosis

  2015influential reference
• Atypical Femoral Fractures: A Teaching Perspective

  2015cited by this paper
• Time course of bone mineral density changes with denosumab compared with other drugs in postmenopausal osteoporosis: a dose-response-based meta-analysis.

  2014cited by this paper
• Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: efficacy and safety results from a randomized open-label study.

  2014influential reference
• Denosumab in osteoporosis

  2014cited by this paper
• The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses

  2014influential reference
• Update on long-term treatment with bisphosphonates for postmenopausal osteoporosis: a systematic review.

  2014cited by this paper
• Clinical Trials Express: Fracture Risk Reduction With Denosumab in Japanese Postmenopausal Women and Men With Osteoporosis: Denosumab Fracture Intervention Randomized Placebo Controlled Trial (DIRECT)

  2014cited by this paper
• High-Resolution Peripheral Quantitative Computed Tomography for the Assessment of Bone Strength and Structure: A Review by the Canadian Bone Strength Working Group

  2013cited by this paper
• Cochrane Handbook for Systematic Reviews of Interventions, Version 5.1.0. The Cochrane Collaboration

  2013cited by this paper
• Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial.

  2013influential reference
• Denosumab Compared With Ibandronate in Postmenopausal Women Previously Treated With Bisphosphonate Therapy: A Randomized Open-Label Trial

  2013influential reference
• Diagnosis and management of osteoporosis in postmenopausal women and older men in the UK: National Osteoporosis Guideline Group (NOGG) update 2013.

  2013cited by this paper
• Atypical Femoral fractures: A Review of the Literature

  2013cited by this paper
• Effect of denosumab on bone mineral density and biochemical markers of bone turnover: 8-year results of a phase 2 clinical trial

  2012cited by this paper
• Five Years of Denosumab Exposure in Women With Postmenopausal Osteoporosis: Results From the First Two Years of the FREEDOM Extension

  2012cited by this paper
• Atypical Subtrochanteric and Diaphyseal Femoral Fractures: Second Report of a Task Force of the American Society for Bone and Mineral Research

  2011cited by this paper
• GRAND: the German retrospective cohort analysis on compliance and persistence and the associated risk of fractures in osteoporotic women treated with oral bisphosphonates

  2011cited by this paper
• The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials

  2011cited by this paper
• Five Years of Cenosumab Exposure in Women With Postmenopausal Osteoporosis: Results From the First Two Years of the FREEDOM Extension

  2011cited by this paper
• Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials

  2011cited by this paper
• Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women

  2011cited by this paper
• Adherence, preference, and satisfaction of postmenopausal women taking denosumab or alendronate

  2011cited by this paper
• Cochrane handbook for systematic reviews of interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration

  2011cited by this paper
• Adherence and profile of non-persistence in patients treated for osteoporosis—a large-scale, long-term retrospective study in The Netherlands

  2010cited by this paper
• American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis.

  2010cited by this paper
• Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy

  2010influential reference
• Six-Year Safety and Efficacy Data from Denosumab Phase 2 Extension Study

  2010cited by this paper
• Activation of β‐Catenin Signaling in Articular Chondrocytes Leads to Osteoarthritis‐Like Phenotype in Adult β‐Catenin Conditional Activation Mice

  2009cited by this paper
• Canadian Agency for Drugs and Technologies in Health

  2009cited by this paper
• Denosumab for prevention of fractures in postmenopausal women with osteoporosis.

  2009influential reference
• The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration

  2009influential reference
• Effects of denosumab on bone mineral density and bone turnover in postmenopausal women.

  2008cited by this paper
• Single-site vs multisite bone density measurement for fracture prediction.

  2007cited by this paper
• Biology of RANK, RANKL, and osteoprotegerin

  2007cited by this paper
• Denosumab in postmenopausal women with low bone mineral density.

  2006cited by this paper
• Cochrane Handbook for Systematic Reviews of Interventions Edited by Julian P. T. Higgins &

  2006cited by this paper
• Regulation of Osteoclast Formation and Function*

  2004cited by this paper
• American Association of Clinical Endocrinologists medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis: 2001 edition, with selected updates for 2003.

  2003cited by this paper
• RANK ligand and the regulation of skeletal remodeling.

  2003cited by this paper
• Evaluating non-randomised intervention studies.

  2003influential reference
• Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis.

  2000cited by this paper
• Bias in meta-analysis detected by a simple, graphical test

  1997influential reference

• Anti-osteoporotic effects of Boswellia serrata gum resin extract in vitro and in vivo

  2024cites this paper
• Sequential treatment from bisphosphonate to denosumab improves lumbar spine bone mineral density in postmenopausal osteoporosis patients: A meta-analysis of randomized controlled trials

  2024cites this paper
• Sequential management of postmenopausal health and osteoporosis: An update.

  2023cites this paper
• Perioperative Considerations in Lumbar Fusion Surgery

  2023cites this paper
• Recommendations for the Pharmacological Treatment of Osteoporosis – Update 2023 of the German Osteoporosis Guideline

  2022cites this paper
• Osteopathy in mild adrenal Cushing's syndrome and Cushing disease.

  2021cites this paper
• β-Boswellic Acid Inhibits RANKL-Induced Osteoclast Differentiation and Function by Attenuating NF-κB and Btk-PLCγ2 Signaling Pathways

  2021cites this paper
• A survey of the feasibility of developing osteoporosis clinical trials in Duchenne muscular dystrophy: Survey of the opinion of young people with Duchenne muscular dystrophy, families and clinicians

  2020cites this paper
• Pharmacological interventions targeting bone diseases in adjunction with bone grafting

  2020cites this paper
• The challenge of long-term adherence: The role of bone turnover markers in monitoring bisphosphonate treatment of osteoporosis.

  2020cites this paper
• The therapeutic efficacy of denosumab for the loss of bone mineral density in glucocorticoid-induced osteoporosis: a meta-analysis

  2020cites this paper
• The Belgian Bone Club 2020 guidelines for the management of osteoporosis in postmenopausal women.

  2020cites this paper
• Osteoporosis in Patients with Chronic Kidney Diseases: A Systemic Review

  2020cites this paper
• Osteoporosis and Spine Surgery: A Critical Analysis Review.

  2020cites this paper
• Advances in Clinical Endocrinology and Metabolism Suppressible RANK-Ligand Levels in a Patient with Trichorhinophalangeal Syndrome Type II on Denosumab Therapy

  2019cites this paper
• Comparative efficacy and safety of pharmacological interventions for osteoporosis in postmenopausal women: a network meta-analysis (Chongqing, China).

  2019cites this paper
• Current and emerging osteoporosis pharmacotherapy for women: state of the art therapies for preventing bone loss

  2019cites this paper
• Protective Effects of Fermented Oyster Extract against RANKL-Induced Osteoclastogenesis through Scavenging ROS Generation in RAW 264.7 Cells

  2019cites this paper
• Stimulation of osteogenic differentiation in bone marrow stromal cells via Wnt/β-catenin pathway by Qili Jiegu-containing serum.

  2018cites this paper
• Denosumab in the treatment of glucocorticoid-induced osteoporosis

  2018cites this paper